AR and prostate cancer: Androgen deprivation therapy (ADT), which is used to block AR or eliminate AR ligands, initially works to inhibit the growth of prostate cancers as a frontline treatment, but over time castrate-resistant prostate cancer (CRPC) occurs through loss of ADT sensitivity [132].